Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13630345 | 0.93 | DRD2 (0.58) | DRD2DRD3 | |
| SCHEMBL17226474 | 0.93 | DRD2 (0.58) | DRD2DRD3 | |
| SCHEMBL13630407 | 0.92 | DRD2 (0.57) | DRD2DRD3 | |
| SCHEMBL14346794 | 0.92 | DRD2 (0.57) | DRD2DRD3 | |
| SCHEMBL13630327 | 0.90 | DRD2 (0.65) | DRD2DRD3 | |
| SCHEMBL14346705 | 0.90 | DRD2 (0.65) | DRD2DRD3 | |
| SCHEMBL14346739 | 0.88 | DRD2 (0.68) | DRD2DRD3 | |
| SCHEMBL13630224 | 0.88 | DRD2 (0.68) | DRD2DRD3 | |
| SCHEMBL13630346 | 0.87 | DRD2 (0.53) | DRD2DRD3 | |
| SCHEMBL14346776 | 0.87 | DRD2 (0.53) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140199232-A1 | Targeted Therapeutic Nanoparticles | NANODERM SCIENCES, INC. (US) | 2014-07-17 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | DRD2 4/4885DRD3 1/4885 |
| US-20140199232-A1 | Targeted Therapeutic Nanoparticles | CD44, PHOSPHO1, CD47 | DRD2 2626/4885DRD3 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.